z-logo
open-access-imgOpen Access
Myeloproliferative neoplasms cause glomerulopathy
Author(s) -
Samar M. Said,
Nelson Leung,
Sanjeev Sethi,
Lynn D. Cornell,
Mary E. Fidler,
Joseph P. Grande,
Sandra M. Herrmann,
Ayalew Tefferi,
Vivette D. D’Agati,
Samih H. Nasr
Publication year - 2011
Publication title -
kidney international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.499
H-Index - 276
eISSN - 1523-1755
pISSN - 0085-2538
DOI - 10.1038/ki.2011.147
Subject(s) - myelofibrosis , medicine , thrombotic microangiopathy , glomerulopathy , nephrotic syndrome , pathology , myeloproliferative neoplasm , myeloproliferative disorders , essential thrombocythemia , chronic myelogenous leukemia , polycythemia vera , renal biopsy , kidney disease , biopsy , leukemia , gastroenterology , proteinuria , bone marrow , disease , kidney
Myeloproliferative neoplasms are clonal hematopoietic stem cell disorders that can produce an undefined glomerulopathy. To better characterize the glomerular disease associated with myeloproliferative neoplasms, we evaluated features of 11 patients with myeloproliferative neoplasm-related glomerulopathy that included 8 patients with primary myelofibrosis, and 1 each with chronic myelogenous leukemia, polycythemia vera, and essential thrombocythemia. Indications for biopsy were nephrotic-range proteinuria (nephrotic syndrome in four) and chronic renal insufficiency. The mean time from diagnosis of the neoplasms to biopsy was 7.2 years. Histologically, mesangial sclerosis and hypercellularity were seen in all 11 cases, segmental sclerosis in 8, features of chronic thrombotic microangiopathy in 9, and intracapillary hematopoietic cells in 4. On follow-up, seven patients had persistent renal dysfunction and four progressed to end-stage renal disease (ESRD). Thus, glomerulopathy appears to be a late complication of myeloproliferative neoplasms, particularly primary myelofibrosis, with guarded prognosis. Greater awareness of this entity and larger studies are needed to define possible therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom